| Literature DB >> 35885499 |
Felix Schön1, Rebecca Sinzig1, Felix Walther2,3, Christoph Georg Radosa1, Heiner Nebelung1, Maria Eberlein-Gonska2, Ralf-Thorsten Hoffmann1, Jens-Peter Kühn1, Sophia Freya Ulrike Blum1,2.
Abstract
Radiological reporting errors have a direct negative impact on patient treatment. The purpose of this study was to investigate the contribution of clinical information (CI) in radiological reporting of oncological imaging and the dependence on the radiologists' experience level (EL). Sixty-four patients with several types of carcinomas and twenty patients without tumors were enrolled. Computed tomography datasets acquired in primary or follow-up staging were independently analyzed by three radiologists (R) with different EL (R1: 15 years; R2: 10 years, R3: 1 year). Reading was initially performed without and 3 months later with CI. Overall, diagnostic accuracy and sensitivity for primary tumor detection increased significantly when receiving CI from 77% to 87%; p = 0.01 and 73% to 83%; p = 0.01, respectively. All radiologists benefitted from CI; R1: 85% vs. 92%, p = 0.15; R2: 77% vs. 83%, p = 0.33; R3: 70% vs. 86%, p = 0.02. Overall, diagnostic accuracy and sensitivity for detecting lymphogenous metastases increased from 80% to 85% (p = 0.13) and 42% to 56% (p = 0.13), for detection of hematogenous metastases from 85% to 86% (p = 0.61) and 46% to 60% (p = 0.15). Specificity remained stable (>90%). Thus, CI in oncological imaging seems to be essential for correct radiological reporting, especially for residents, and should be available for the radiologist whenever possible.Entities:
Keywords: clinical information; computed tomography; oncological imaging; quality assurance; radiological report
Year: 2022 PMID: 35885499 PMCID: PMC9321157 DOI: 10.3390/diagnostics12071594
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Comparison of baseline demographic features.
| Cancer Disease Present | Cancer Disease Absent | ||
|---|---|---|---|
| Number | 64 | 20 | - |
| Male (%) | 49 (76.6%) | 12 (60%) | 0.27 |
| Median age (years) + IQR | 64.5 (58–72) | 58.5 (41–68.25) | 0.06 |
List of absolute and relative frequencies of the different tumor entities and locations of lymphogenous and hematogenous metastases.
|
|
|
| Bronchial | n = 9 (14%) |
| Gastroesophageal | n = 9 (14%) |
| Bladder | n = 9 (14%) |
| Renal | n = 9 (14%) |
| Hepatocellular | n = 9 (14%) |
| Pancreatic | n = 9 (14%) |
| Lymphoma | n = 10 (16%) |
|
|
|
| Thoracic | n = 8 (36%) |
| Abdominal | n = 11 (50%) |
| Iliac/Inguinal | n = 3 (14%) |
|
|
|
| Hepatic | n = 8 (44%) |
| Pulmonary | n = 2 (11%) |
| Bone | n = 4 (22%) |
| Other | n = 4 (22%) |
Accuracy, sensitivity, and specificity of diagnostic performance for primary tumor detection depending on absence or presence of clinical information (CI).
| Accuracy | Sensitivity | Specificity | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No CI | Given CI | No CI | Given CI | No CI | Given CI | ||||
|
| 77% | 87% | 0.01 | 73% | 83% | 0.01 | 92% | 98% | 0.15 |
|
| 85% | 92% | 0.15 | 84% | 91% | 0.28 | 85% | 95% | 0.6 |
|
| 77% | 83% | 0.33 | 70% | 78% | 0.31 | 100% | 100% | 1.00 |
|
| 70% | 86% | 0.02 | 64% | 81% | 0.01 | 95% | 100% | 0.48 |
|
| 0.09 | 0.25 | - | 0.03 | 0.14 | - | 0.31 | 1.00 | - |
Figure 1Receiver operating characteristic curves (ROC) showing the diagnostic performance of primary tumor detection over all radiologists whether clinical information (CI) was provided. Area under the curve (AUC) without CI = 0.83; with CI = 0.91. See Appendix A for ROC and AUC values for each reader.
Number of correctly identified primary tumors listed per entity depending on absence or presence of clinical information (CI).
| Number of Identified Tumors per Entity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reader 1 | Reader 2 | Reader 3 | Overall | ||||||
| Entity | No CI | Given CI | No CI | Given CI | No CI | Given CI | No CI | Given CI | |
|
| 7/9; 78% | 9/9; 100% | 6/9; 67% | 8/9; 89% | 4/9; 44% | 7/9; 78% | 17/27; 63% | 24/27; 89% | 0.05 |
|
| 8/9; 89% | 9/9; 100% | 6/9; 67% | 7/9; 78% | 5/9; 56% | 6/9; 67% | 19/27; 70% | 22/27; 81% | 0.53 |
|
| 9/9; 100% | 9/9; 100% | 9/9; 100% | 8/9; 89% | 8/9; 89% | 9/9; 100% | 26/27; 96% | 26/27; 96% | 1.00 |
|
| 9/9; 100% | 9/9; 100% | 7/9; 78% | 8/9; 89% | 8/9; 89% | 9/9; 100% | 24/27; 89% | 26/27; 96% | 0.61 |
|
| 7/9; 78% | 7/9; 78% | 6/9; 67% | 5/9; 56% | 7/9; 78% | 7/9; 78% | 20/27; 74% | 19/27; 70% | 1.00 |
|
| 7/9; 78% | 8/9; 89% | 5/9; 56% | 7/9; 78% | 5/9; 56% | 7/9; 78% | 17/27; 63% | 22/27; 81% | 0.22 |
|
| 7/10; 70% | 7/10; 70% | 6/10; 60% | 7/10; 70% | 4/10; 40% | 7/10; 70% | 17/30; 57% | 21/30; 70% | 0.42 |
Comparison of sensitivities for primary tumor detection per entity vs. reported data in the literature [11,12,13,14,15,16,17]. CI = Clinical information.
| Primary Tumor | Sensitivity in the Present Study (Given CI) | Sensitivity in Literature |
|---|---|---|
| Bronchial | 89% | 98% |
| Gastroesophageal | 81% | 96%/42% (a) |
| Bladder | 96% | 95% |
| Renal | 96% | 88% |
| Hepatocellular | 70% | 66% |
| Pancreatic | 81% | 76%/92% (b) |
| Lymphoma | 70% | 89% |
(a) gastric cancer/esophageal cancer; (b) depending on size (<2 cm vs. >2 cm).
Figure 2Pancreatic cancer (arrow). Correctly identified by one radiologist without and by all three radiologists with given clinical information (Conspicuous pancreas lesion seen in abdominal ultrasound. Laryngeal carcinoma several years ago.).
Figure 3Pancreatic cancer (arrow). All readers identified the lesion in absence and presence of clinical information (Recurrent epigastric pressure and 9 kg weight loss in 4 months.).
Figure 4Hepatocelluar carcinoma in the right lobe (arrow). (a) Low contrast enhancement in the arterial phase. (b) Washout in the venous phase. All readers did not report the nodule whether clinical information was provided (Seizure after alcohol withdrawal. Known liver cirrhosis and hepatosplenomegaly.).
Figure 5Subpleural bronchial carcinoma in the left lower lobe (arrow). Correctly identified by one radiologist without and by all three radiologists with given clinical information (Pain left hip with radiation into thoracic wall. Limited mobilization, reduced appetite. Obscure lesion of the lung on previous imaging.).
Figure 6Comparison of sensitivities and specificities for metastasis detection per entity vs. reported data in the literature [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. Lymph node metastasis on the left, hematogenous metastasis on the right.
True and false positive/negative findings for primary tumor detection per reader on absence or presence of clinical information (CI).
| True and False Positive/Negative Findings for Primary Tumor Detection | |||||||
|---|---|---|---|---|---|---|---|
| Reader 1 | Reader 2 | Reader 3 | |||||
| Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | ||
|
|
| 54 (84%) | 3 (15%) | 45 (70%) | 0 (0%) | 41 (64%) | 1 (5%) |
|
| 10 (16%) | 17 (85%) | 19 (30%) | 20 (100%) | 23 (36%) | 19 (95%) | |
|
|
| 58 (91%) | 1 (5%) | 50 (78%) | 0 (0%) | 52 (81%) | 0 (0%) |
|
| 6 (9%) | 19 (95%) | 14 (22%) | 20 (100%) | 12 (19%) | 20 (100%) | |
True and false positive/negative findings for lymph node metastases detection per reader on absence or presence of clinical information (CI).
| True and False Positive/Negative Findings for Lymph Node Metastasis Detection | |||||||
|---|---|---|---|---|---|---|---|
| Reader 1 | Reader 2 | Reader 3 | |||||
| Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | ||
|
|
| 5 (26%) | 6 (9%) | 11 (58%) | 6 (9%) | 8 (42%) | 5 (8%) |
|
| 14 (74%) | 59 (91%) | 8 (42%) | 59 (91%) | 11 (58%) | 60 (92%) | |
|
|
| 5 (26%) | 1 (2%) | 13 (68%) | 4 (6%) | 14 (74%) | 7 (11%) |
|
| 14 (74%) | 64 (98%) | 6 (32%) | 61 (94%) | 5 (26%) | 58 (89%) | |
True and false positive/negative findings for hematogenous metastases detection per reader on absence or presence of clinical information (CI).
| True and False Positive/Negative Findings for Hematogenous Metastasis Detection | |||||||
|---|---|---|---|---|---|---|---|
| Reader 1 | Reader 2 | Reader 3 | |||||
| Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | Positive to Gold Standard (n) | Negative to Gold Standard (n) | ||
|
|
| 9 (56%) | 3 (4%) | 9 (56%) | 5 (7%) | 5 (31%) | 6 (9%) |
|
| 7 (44%) | 65 (96%) | 7 (44%) | 63 (93%) | 11 (69%) | 62 (91%) | |
|
|
| 9 (56%) | 3 (4%) | 10 (62.5%) | 4 (6%) | 10 (62.5%) | 9 (13%) |
|
| 7 (44%) | 65 (96%) | 6 (37.5%) | 64 (94%) | 6 (37.5%) | 59 (87%) | |